Radar›Companies›Surgical And Medical Instruments And Apparatus Stocks in USA: Revenue Cohort 12
United States surgical and medical instruments and apparatus industry landscape illustrating listed-company operations, infrastructure and market activity
Prism Finance USA · comparison snapshot

Surgical And Medical Instruments And Apparatus Stocks in USA: Revenue Cohort 12

A five-company surgical and medical instruments and apparatus cohort selected by latest filing revenue, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 23 October 2026Not investment adviceRanked by Prism readiness
Readiness leaderPetVivo · 52
Strongest available pathHarvard Apparatus Regenerative Technology · -36.7%
Widest latest marginElectromedical Technologies · -195.8%
Companies compared5 · U.S.-listed
01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1PETV · OTC

PetVivo

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2021Minneapolis, Minnesota$26.6M market cap
View full Companies Radar profile
52Moderate
Snapshot price$0.70as of page date
Monthly-close return-73.4%five-year window
FY2025 revenue$0.00BPetVivo Holdings, Inc.
Net margin-741.6%FY2025
Prism attention14.1%share across these five
Filing track recordRevenue, USD billions
+8904.1%
$0$0.0B$0.0B$0.0BFY2021: $0.000BFY2022: $0.000BFY2023: $0.001BFY2024: $0.001BFY2025: $0.001B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 208.0%
52-week position10% through range
$0.59$1.69
News mentions267
Community mentions0partial coverage
U.S.-scope patents9
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal81/100
Management stability90/100
Market position7/100
Capital-event signal35/100
Innovation pulse20/100
Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 1 lifetime product-launch events, 1 in the latest 360 days, and 1 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2CODX · Nasdaq

Co-Diagnostics

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2012Salt Lake City, Utah$3.8M market cap
View full Companies Radar profile
48Cautious
Snapshot price$0.55as of page date
Monthly-close return-99.8%five-year window
FY2025 revenue$0.00BCo-Diagnostics, Inc.
Net margin-7533.6%FY2025
P/E snapshot-0.7xone ratio, not a verdict
Prism attention57.4%share across these five
Filing track recordRevenue, USD billions
-99.4%
$0$0.0B$0.1B$0.1BFY2021: $0.098BFY2022: $0.034BFY2023: $0.007BFY2024: $0.004BFY2025: $0.001B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -71.8%
52-week position0% through range
$0.53$46.50
News mentions1.1K
Community mentions0partial coverage
U.S.-scope patents2
Prism Insights

What sits behind the readiness signal

Observed risk 8/100higher means more observed risk
Earnings signal70/100
Management stability90/100
Market position3/100
Capital-event signal71/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 0 asset-acquisition events and 4 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 3 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3SINT · Nasdaq

SINTX

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 1996Salt Lake City$11.9M market cap
View full Companies Radar profile
41Cautious
Snapshot price$1.58as of page date
Monthly-close return-100.0%five-year window
FY2025 revenue$0.00BSintx Technologies, Inc.
Net margin-1018.1%FY2025
P/E snapshot-1.5xone ratio, not a verdict
Prism attention19.1%share across these five
Filing track recordRevenue, USD billions
+68.0%
$0$0.0B$0.0B$0.0BFY2021: $0.001BFY2022: $0.002BFY2023: $0.003BFY2024: $0.003BFY2025: $0.001B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 13.8%
52-week position6% through range
$1.40$4.46
News mentions362
Community mentions34partial coverage
U.S.-scope patents173
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal32/100
Management stability90/100
Market position6/100
Capital-event signal72/100
Innovation pulse5/100
Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 1 asset-acquisition events and 3 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4HRGN · OTC

Harvard Apparatus Regenerative Technology

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2012Holliston, Massachusetts$39.8M market cap
View full Companies Radar profile
35Cautious
Snapshot price$1.96as of page date
Monthly-close return-36.7%five-year window
FY2025 revenue$0.00BHarvard Apparatus Regenerative Technology, Inc.
Net margin-975.7%FY2025
Prism attention6.8%share across these five
Filing track recordRevenue, USD billions
+496.6%
$0$0.0B$0.0B$0.0BFY2015: $0.000BFY2016: $0.000BFY2023: $0.000BFY2024: $0.000BFY2025: $0.001B20152016202320242025
FY2015–FY2025 · 5 filing periods · TOTAL REVENUE · Revenue derived as cost of revenue plus gross profit for FY2015, FY2016 · CAGR 56.3%
52-week position67% through range
$0.96$2.46
News mentions130
Community mentions0partial coverage
U.S.-scope patents21
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal50/100
Management stability90/100
Market position0/100
Capital-event signal15/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5EMED · OTC

Electromedical Technologies

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2007Phoenix, Arizona$0.4M market cap
View full Companies Radar profile
24Avoid
Snapshot price$0.00as of page date
Monthly-close return-99.8%five-year window
FY2023 revenue$0.00BElectromedical Technologies, Inc
Net margin-195.8%FY2023
Prism attention2.6%share across these five
Filing track recordRevenue, USD billions
+82.8%
$0$0.0B$0.0B$0.0BFY2020: $0.001BFY2021: $0.001BFY2022: $0.001BFY2023: $0.001B2020202120222023
FY2020–FY2023 · 4 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 22.3%
52-week position50% through range
$0.00$0.00
News mentions50
Community mentions0partial coverage
U.S.-scope patents0
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal34/100
Management stability70/100
Market position0/100
Capital-event signal0/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Harvard Apparatus Regenerative Technology
-36.7%
PetVivo
-73.4%
Co-Diagnostics
-99.8%
Electromedical Technologies
-99.8%
SINTX
-100.0%

Latest revenue

USD billions, official filing scope shown on each company card.

PetVivo
$0.00B
Co-Diagnostics
$0.00B
SINTX
$0.00B
Harvard Apparatus Regenerative Technology
$0.00B
Electromedical Technologies
$0.00B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Electromedical Technologies
-195.8%
PetVivo
-741.6%
Harvard Apparatus Regenerative Technology
-975.7%
SINTX
-1018.1%
Co-Diagnostics
-7533.6%

Prism news attention

Normalized share across these five names; attention is not quality.

Co-Diagnostics
57.4%
SINTX
19.1%
PetVivo
14.1%
Harvard Apparatus Regenerative Technology
6.8%
Electromedical Technologies
2.6%
03 · Prism readout

What the signals say—and what they do not

The headline share is normalized surgical and medical instruments and apparatus news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Co-Diagnostics leads the conversation

It holds 57.4% of measured surgical and medical instruments and apparatus news attention and also carries the basket's largest revenue base at $0.00B.

Price path

Harvard Apparatus Regenerative Technology leads the available price paths

Its monthly-close return is -36.7% for the five-year window. At the other end, SINTX is -100.0% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Electromedical Technologies has the widest latest margin

Its FY2023 net margin is -195.8%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

SINTX shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -1.5x while its five-year window price return is -100.0%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · CODX

Co-Diagnostics

1,090available Prism news records

Prism top themes

Earnings & financial performance
76
Price action & investor response
42
Legal, arbitration & regulatory
11
Capital allocation & transactions
8
Leadership & governance
4

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+114.0%199 latest 12m vs 93 prior 12m
2024-01: 2 mentions2024-02: 5 mentions2024-03: 14 mentions2024-04: 7 mentions2024-05: 4 mentions2024-06: 6 mentions2024-07: 3 mentions2024-08: 9 mentions2024-09: 4 mentions2024-10: 4 mentions2024-11: 6 mentions2024-12: 5 mentions2025-01: 8 mentions2025-02: 19 mentions2025-03: 24 mentions2025-04: 5 mentions2025-05: 6 mentions2025-06: 0 mentions2025-07: 3 mentions2025-08: 12 mentions2025-09: 18 mentions2025-10: 32 mentions2025-11: 21 mentions2025-12: 14 mentions2026-01: 7 mentions2026-02: 8 mentions2026-03: 29 mentions2026-04: 17 mentions2026-05: 32 mentions2026-06: 6 mentions2024-012026-06

Machine-classified coverage tone

83.9% positive+8.6 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

molecular diagnostics 20pcr testing 20stock price 18stock performance 17earnings report 14share price 14rt-pcr diagnostics 13rapid antigen tests 13

Keyword tag occurrences in available Prism news records.

Coverage: 2011-04-01–2026-06-03 · trend and themes shown through 2026-06
05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

SINT

SINTX

34 mentions
Stock and valuation
24
Products, pricing and logistics
3

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 34 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

PETV

PetVivo

through 2026-04-29
Earnings releases 11Leadership changes 7Company announcements 2Business contracts 1
  1. Business contracts

    Peer to Peer Network's AI partner Tier 1 AI will install three tags and deliver up to 3,000 investor profiles a month.

  2. Earnings releases

    Revenues totaled $303,000, up 51% from the same year-ago quarter.

  3. Company announcements

    PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW) and its wholly-owned subsidiary Petvivo Animal Health, Inc., a leading biomedical company delivering innovative medical devices and therapeutics for equines and companion animals, will hold a conference call on Friday, November 14, 2025 at 5:00 p.m. Eastern time to discuss results for the fiscal second quarter ended September 30, 2025.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

CODX

Co-Diagnostics

through 2026-04-02
Earnings releases 18Regulatory 3Listing / IPO 2Leadership changes 1
  1. Regulatory

    What the announcement does do is extend the strategic narrative: Co-Diagnostics is now simultaneously pursuing clinical validation in India through CoSara, regulatory approval of its PCR Pro platform in the United States, and industrial infrastructure development in Saudi Arabia.

  2. Listing / IPO

    In a separate filing, Co-Diagnostics disclosed an at-the-market equity offering program of up to $10 million through an Equity Distribution Agreement with Maxim Group LLC.

  3. Earnings releases

    Revenue of $0.2 million , which declined from $2.7 million during Q2 2024 primarily due to timing of grant revenue recognition.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

SINT

SINTX

through 2026-04-14
Leadership changes 16Earnings releases 9Business contracts 3Asset acquisitions 1Company announcements 1
  1. Earnings releases

    Ascendiant Capital Markets issued their Q1 2027 earnings per share (EPS) estimates for Sintx Technologies in a note issued to investors on Tuesday, April 7th. Ascendiant Capital Markets analyst E. Woo expects that the company will earn ($0.48) per share for the quarter.

  2. Leadership changes

    SINTX announces promotion of David O’Brien to chief operating officer SINTX Technologies, an OEM ceramics company, announced the promotion of David O’Brien to chief operating officer.

  3. Asset acquisitions

    SINTX Technologies, Inc. (NASDAQ: SINT), a Salt Lake City-based advanced ceramics company, acquired the surgical business assets of SiNAPTIC Holdings, LLC, a privately held silicon nitride ceramic manufacturer, in an all-equity transaction valued at $750,000 in common shares.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

HRGN

Harvard Apparatus Regenerative Technology

through 2025-02-14
Earnings releases 2Leadership changes 2
  1. Leadership changes

    Harvard Apparatus Regenerative Technology Inc., of Holliston, Mass., named Laura Mondano vice president of regulatory affairs.

  2. Earnings releases

    For the three months ended March 31, 2024, the Company reported a net loss of $2.0 million, ($0.15) per share, compared to a net loss of $3.0 million, ($0.24) per share, for the three months ended March 31, 2023.

  3. Leadership changes

    Harvard Apparatus Regenerative Technology, Inc. ("Harvard Apparatus Regenerative Technology" or the "Company"), a clinical-stage biotechnology company developing the technology to regenerate organs inside the body to treat severe diseases, today announced the appointment of Mao Zhang as an independent director to its Board of Directors.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

EMED

Electromedical Technologies

through 2024-08-14
Earnings releases 8
  1. Earnings releases

    Electromedical Technologies reported Q2 FY2024 revenue of $0.2M in the official-filing series.

  2. Earnings releases

    Electromedical Technologies reported Q1 FY2024 revenue of $0.3M in the official-filing series.

  3. Earnings releases

    Electromedical Technologies reported FY2023 revenue of $1.3M in the official-filing series.

Cached Prism company-event evidence fallback; totals describe available coverage and the displayed highlights prefer filing-backed earnings rows.

07 · Industry landscape

Surgical And Medical Instruments And Apparatus Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary surgical and medical instruments and apparatus news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

surgical instruments market

9 sources77.7% extraction confidence
2019 extracted base$10.20B–$11.75B
2025 extracted forecast$11.50B–$21.52B
Implied source CAGR7.4%
increasing number of surgical proceduresrising prevalence of chronic diseasesincreasing prevalence of chronic diseases

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, Asia Pacific, Europe, North America. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Surgical And Medical Instruments And Apparatus news pulse

84,236available Prism news records
Latest 12m volume+8.7%36648 vs 33721 records
Positive classified tone64.5%+2.3 pp vs prior four quarters
2024-01: 2,862 mentions2024-02: 2,508 mentions2024-03: 2,665 mentions2024-04: 2,848 mentions2024-05: 2,984 mentions2024-06: 2,155 mentions2024-07: 2,123 mentions2024-08: 2,108 mentions2024-09: 2,116 mentions2024-10: 2,483 mentions2024-11: 2,604 mentions2024-12: 2,045 mentions2025-01: 2,853 mentions2025-02: 5,160 mentions2025-03: 3,909 mentions2025-04: 3,553 mentions2025-05: 2,612 mentions2025-06: 1,780 mentions2025-07: 3,188 mentions2025-08: 7,906 mentions2025-09: 2,642 mentions2025-10: 2,462 mentions2025-11: 2,103 mentions2025-12: 2,450 mentions2026-01: 1,736 mentions2026-02: 4,268 mentions2026-03: 3,588 mentions2026-04: 4,213 mentions2026-05: 312 mentions2024-012026-05
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3
26Q4

Available U.S.-primary Prism records matching instrument, medical, surgical. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

cannabis legalization debates
7,802
medical drama series
7,076
cannabis legalization trends & economic impact
6,207
recreational marijuana usage
5,579
in-flight medical emergency protocols
4,688
medical marijuana laws & regulatory frameworks
3,617

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

cannabis policy reform discussions 7,316marijuana legalization arguments 6,389weed decriminalization debates 6,068cannabis industry regulations 5,880legal cannabis sales 5,791non-medical cannabis consumption 5,551medical cannabis regulations 5,272state cannabis economies 5,173

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

increasing number of surgical procedures

9 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card
Opportunity · demand

cannabis legalization debates

7,802 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata
Opportunity · innovation

Innovation and product activity

6,624 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule
Caution · market restraint

uncertainty in reimbursements

7,008 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata
Caution · news pulse

Coverage growth can reverse

+8.7% news volume

The latest 12 months contain 36,648 matched records versus 33,721 in the previous window.

Available Prism coverage through 2026-05-05
Caution · sentiment

Classified tone is not demand

64.5% positive · +2.3pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →
08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 3841 (Surgical And Medical Instruments And Apparatus), selected as the first five names that pass all live publication gates from the latest filing revenue candidate pool ranked 56–63. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

  • Official annual filingsFY revenue history and latest profitability
  • U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
  • Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
  • Prism market-growth extractionDated third-party Surgical And Medical Instruments And Apparatus Industry in USA market benchmark with source-count, geography and confidence context
Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 23 October 2026.
09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Scale and margin leadership sit with Electromedical Technologies and Electromedical Technologies

Electromedical Technologies has the largest displayed latest revenue at $0.00B; Electromedical Technologies has the widest displayed latest margin at -195.8%.

Open Electromedical Technologies in Companies Radar
Comparisons

Largest versus smallest displayed revenue base

The latest displayed revenue ranges from $0.00B for Electromedical Technologies to $0.00B for Electromedical Technologies. Entity and filing-period labels remain visible on the company cards.

Open Electromedical Technologies in Companies Radar
Anomalies

PetVivo has the widest attention-readiness rank gap

It ranks #3 by measured news attention (14.1%) and #1 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open PetVivo in Companies Radar

PetVivo shows a price-operating divergence to inspect

Its displayed filing-revenue change is +8904.1% while its available monthly-close return is -73.4%. The signs differ, but the two measures cover different windows and do not establish causality.

Open PetVivo in Companies Radar
Explanations

Attention measures coverage volume, not quality

Co-Diagnostics's 57.4% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Co-Diagnostics in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open PetVivo's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 52/100 score.

Open PetVivo in Companies Radar
Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.
Coming soon